Urgent Threats
■ Carbapenem-resistant Acinetobacter
■ Candida auris (C. auris)
■ Clostridioides difficile (C. difficile)
■ Carbapenem-resistant Enterobacteriaceae (CRE)
■ Drug-resistant Neisseria gonorrhoeae (N. gonorrhoeae)
Serious Threats
■ Drug-resistant Campylobacter
■ Drug-resistant Candida
■ Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae
■ Vancomycin-resistant Enterococci (VRE)
■ Multidrug-resistant Pseudomonas aeruginosa (P. aeruginosa)
■ Drug-resistant nontyphoidal Salmonella
■ Drug-resistant Salmonella serotype Typhi
■ Drug-resistant Shigella
■ Methicillin-resistant Staphylococcus aureus (MRSA)
■ Drug-resistant Streptococcus pneumoniae (S. pneumoniae)
■ Drug-resistant Tuberculosis (TB)
Concerning Threats
■ Erythromycin-resistant group A Streptococcus
■ Clindamycin-resistant group B Streptococcus
This is what ATH has to fight against these threats:
Bohlmann et al paper (gram-positive bacteria): PBT2 exhibits antibacterial activity and disrupts cellular homeostasis in erythromycin-resistant group A Streptococcus (GAS), methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococcus (VRE).
De Oliviera paper (gram-negative bacteria) demonstrated the efficacy that PBT2 can break the resistance to polymyxin class antibiotics in Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa.
Jen FE, El-Deeb IM et al paper about PBT2 in gonorrhea.
I would expect some more research is still on the way to fill the caps of PBT2 on the list of CDC.
- Forums
- ASX - By Stock
- Antibiotic-resistant problem: Urgent, serious and concerns of CDC (USA)
Urgent Threats ■ Carbapenem-resistant Acinetobacter■ Candida...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATH (ASX) to my watchlist
|
|||||
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.28M |
Open | High | Low | Value | Volume |
0.4¢ | 0.4¢ | 0.4¢ | $5.012K | 1.294M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
43 | 54662006 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 126993867 | 29 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
42 | 54412006 | 0.003 |
55 | 84168098 | 0.002 |
25 | 120860100 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 125993867 | 28 |
0.005 | 25809782 | 26 |
0.006 | 12956477 | 18 |
0.007 | 47601651 | 22 |
0.008 | 22833132 | 23 |
Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |
The Watchlist
UNT
UNITH LTD
Idan Schmorak, CEO
Idan Schmorak
CEO
Previous Video
Next Video
SPONSORED BY The Market Online